Sincalide Injection

One of the core applications of Sincalide Injection is the dynamic evaluation of gallbladder contractile function. It is widely compatible with various imaging modalities including ultrasonography, cholecystography, and radionuclide imaging, representing a key clinical tool for identifying abnormal gallbladder function. Its primary uses cover the diagnosis and assessment of various gallbladder disorders, such as screening and confirmation of suspected chronic cholecystitis, gallbladder contractile dysfunction, and adenomyomatosis. Following intravenous administration, it evokes physiological gallbladder contraction, allowing observation of contraction amplitude, rhythm, and time to peak response to determine functional normality.

For patients with gallbladder polyps or cholelithiasis, this product is used for preoperative gallbladder function assessment to clarify contractile reserve, providing critical evidence for patient selection in gallbladder-preserving surgery and avoiding postoperative complications due to severely impaired gallbladder function. Additionally, it replaces the traditional fat meal test in scenarios requiring precise, reproducible results free from interindividual digestive variations and dietary influences, especially for patients with insufficient fasting time, weak digestive function, or inability to tolerate a fat meal.

Compared with the fat meal, peak contraction is achieved within 5–15 minutes after intravenous injection, with faster and more stable responses, effectively improving diagnostic efficiency and accuracy while reducing errors caused by variable fat meal digestion and absorption. For patients fasting for more than 24 hours, it can empty gallbladder bile prior to imaging, enhancing visualization and aiding detection of minor lesions.

Sincalide Injection is frequently used in combination with secretin, forming the gold-standard protocol for evaluating exocrine pancreatic function. It is widely applied in the diagnosis and functional assessment of various pancreatic diseases and represents a core clinical method for evaluating pancreatic parenchymal function. Indications include diagnosis and staging of chronic pancreatitis, pancreatic cancer, cystic fibrosis, and postoperative pancreatic insufficiency, especially for screening early subclinical pancreatic dysfunction.

It addresses the limitation of CT, MRI, and other imaging modalities, which only show morphological changes without reflecting secretory function.Secretin primarily acts on pancreatic ductal cells to stimulate water and bicarbonate secretion, while sincalide targets pancreatic acinar cells to induce release of digestive enzymes including amylase, lipase, and proteases.

Together, they comprehensively evaluate secretory volume, bicarbonate concentration, and digestive enzyme activity, fully reflecting exocrine pancreatic function. This protocol supports etiological classification of pancreatic disorders, selection of therapeutic strategies (e.g., guiding dosage adjustment of pancreatic enzyme replacement therapy for exocrine insufficiency), and prognostic assessment through dynamic monitoring of secretory function to evaluate disease progression and treatment response. It is also used to assess graft function following pancreas transplantation.